NTLA

MKT CAP:$2B

Intellia Therapeutics, Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$15.90+$6.69 (+72.64%)

Apr 24, 2026

Company Details

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA...

CEO

John Leonard

IPO Date

May 6, 2016

Website

www.intelliatx.com

Key Metrics TTM

Revenue

$54M

+13.0% YoY

Net Income

-$453M

EPS (Diluted)

-$4.34

Free Cash Flow

-$413M

Revenue / Share

$0.49

Gross Margin

-46.8%

Operating Margin

-905.9%

Net Margin

-841.8%

FCF Margin

-767.5%

P/S

31.0x

P/E

—

Earnings Reports

Q4 2025

May 14, 2026

PENDING

Q3 2025

Nov 6, 2025

$14M+51.3%EPS -$0.92

Q2 2025

Aug 7, 2025

$14M+104.8%EPS -$0.98

Q1 2025

May 8, 2025

$17M-42.5%EPS -$1.10

FY 2024

Feb 27, 2025

$58MEPS -$5.25

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$6M	-$33M	-$46M
Q2 21	$7M	-$52M	-$69M
Q3 21	$7M	-$53M	-$72M
Q4 21	$13M	-$58M	-$80M
Q2 22	$14M	-$76M	-$98M
Q3 22	$13M	-$83M	-$106M
Q4 22	$14M	-$86M	-$110M
Q1 23	$13M	-$85M	-$112M
Q2 23	$14M	-$102M	-$132M
Q4 23	-$2M	-$4M	-$140M
Q1 24	$29M	$26M	-$114M
Q2 24	$7M	$4M	-$139M
Q3 24	$9M	$9M	-$145M
Q1 25	$17M	$17M	-$121M
Q2 25	$14M	$14M	-$110M
Q3 25	$14M	-$65M	-$111M

Valuation

Quarter	P/S	P/E
Q1 21	85.2x	—
Q2 21	217.5x	—
Q3 21	406.0x	—
Q4 21	269.1x	—
Q2 22	99.5x	—
Q3 22	95.8x	—
Q4 22	59.5x	—
Q1 23	61.2x	—
Q2 23	68.0x	—
Q4 23	71.9x	—
Q1 24	46.3x	—
Q2 24	45.1x	—
Q3 24	46.3x	—
Q1 25	11.4x	—
Q2 25	20.7x	—
Q3 25	32.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$55M	-$58M
Q1 22	-$80M	-$126M
Q2 22	-$85M	-$89M
Q3 22	-$79M	-$83M
Q4 22	-$90M	-$94M
Q1 23	-$109M	-$113M
Q2 23	-$90M	-$95M
Q3 23	-$101M	-$106M
Q4 23	-$93M	-$95M
Q1 24	-$121M	-$123M
Q2 24	-$58M	-$59M
Q3 24	-$85M	-$86M
Q4 24	-$85M	-$86M
Q1 25	-$149M	-$150M
Q2 25	-$100M	-$100M
Q3 25	-$77M	-$77M

Capital Expenditures

Quarter	CapEx
Q4 21	$3M
Q1 22	$46M
Q2 22	$4M
Q3 22	$4M
Q4 22	$4M
Q1 23	$4M
Q2 23	$4M
Q3 23	$4M
Q4 23	$2M
Q1 24	$3M
Q2 24	$1M
Q3 24	$1M
Q4 24	$981.0K
Q1 25	$735.0K
Q2 25	$239.0K
Q3 25	$29.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 21	-50.1%	+15.0%
Q2 21	-59.7%	+53.3%
Q3 21	-67.6%	+57.4%
Q4 21	+94.9%	+90.4%
Q2 22	+117.7%	+112.5%
Q3 22	+102.5%	+57.2%
Q4 22	+88.4%	+56.1%
Q1 23	-1.9%	+33.6%
Q2 23	-3.1%	+29.9%
Q4 23	-114.5%	+16.1%
Q1 24	+113.2%	+15.6%
Q2 24	-44.8%	+17.2%
Q3 24	-33.0%	+5.4%
Q1 25	+967.3%	-0.4%
Q2 25	-50.8%	-13.1%
Q3 25	+98.1%	-14.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$15M	113.3%
Q1 22	$18M	—
Q2 22	$23M	164.4%
Q3 22	$25M	190.1%
Q4 22	$25M	181.4%
Q1 23	$27M	216.2%
Q2 23	$36M	267.8%
Q3 23	$35M	—
Q4 23	$35M	—
Q1 24	$34M	118.1%
Q2 24	$41M	587.3%
Q3 24	$40M	434.8%
Q4 24	$40M	—
Q1 25	$22M	131.4%
Q2 25	$22M	154.7%
Q3 25	$20M	142.2%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 21	$39M	$14M	—
Q2 21	$59M	$17M	—
Q3 21	$60M	$19M	—
Q4 21	$71M	$22M	—
Q2 22	$90M	$22M	—
Q3 22	$97M	$22M	—
Q4 22	$100M	$24M	—
Q1 23	$97M	$27M	—
Q2 23	$115M	$31M	—
Q4 23	$109M	$29M	—
Q1 24	$109M	$31M	—
Q2 24	$112M	$32M	—
Q3 24	$123M	$31M	—
Q1 25	$108M	$29M	—
Q2 25	$97M	$27M	—
Q3 25	$95M	$31M	$16M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$133M	$722M	$855M
Q2 22	$148M	$726M	$874M
Q3 22	$141M	$687M	$828M
Q4 22	$524M	$669M	$1.2B
Q1 23	$294M	$639M	$934M
Q2 23	$172M	$736M	$908M
Q3 23	$168M	$687M	$855M
Q4 23	$227M	$685M	$912M
Q1 24	$172M	$619M	$791M
Q2 24	$131M	$560M	$691M
Q3 24	$120M	$538M	$658M
Q4 24	$189M	$412M	$602M
Q1 25	$127M	$377M	$504M
Q2 25	$156M	$303M	$460M
Q3 25	$193M	$318M	$511M
Q4 25	$155M	$294M	$450M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	67M	+9.6%	+33.1%
Q2 21	68M	+1.5%	+27.7%
Q3 21	74M	+8.1%	+25.4%
Q4 21	74M	+1.0%	+21.4%
Q2 22	76M	+1.9%	+12.9%
Q3 22	76M	+0.3%	+11.6%
Q4 22	81M	+6.8%	+10.2%
Q1 23	88M	+8.1%	+17.9%
Q2 23	88M	+0.5%	+16.3%
Q4 23	90M	+2.6%	+19.0%
Q1 24	96M	+5.6%	+17.6%
Q2 24	97M	+1.5%	+10.5%
Q3 24	101M	+4.2%	+14.5%
Q1 25	104M	+2.5%	+14.4%
Q2 25	104M	+0.2%	+8.6%
Q3 25	110M	+6.2%	+13.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	$20.7K	312
Q2 21	$21.0K	312
Q3 21	$23.1K	312
Q4 21	$26.5K	485
Q2 22	$28.9K	485
Q3 22	$27.4K	485
Q4 22	$22.7K	598
Q1 23	$21.1K	598
Q2 23	$22.7K	598
Q4 23	-$3.6K	526
Q1 24	$55.0K	526
Q2 24	$13.2K	526
Q3 24	$17.3K	526
Q1 25	$41.3K	403
Q2 25	$35.3K	403
Q3 25	$34.2K	403

Revenue / Employee